OraSure Technologies Files 8-K Report

TL;DR

OSUR filed an 8-K with SEC - mostly financial statements and exhibits.

AI Summary

On December 19, 2024, OraSure Technologies, Inc. (OSUR) filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific new financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that OraSure Technologies is providing updated financial statements and potentially disclosing other relevant events to the SEC, which is important for investors to monitor company activities.

Risk Assessment

Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain information that inherently increases risk.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
• 2024-12-19 — Filing Date (The date the 8-K report was officially submitted to the SEC.)

Key Players & Entities

• OraSure Technologies, Inc. (company) — Registrant
• OSUR (company) — Trading Symbol
• Nasdaq Stock Market LLC (company) — Exchange
• Delaware (company) — State of Incorporation

FAQ

Key Financial Figures

• $0.000001 — nge on which registered Common Stock, $0.000001 par value per share OSUR The Nasdaq S

Filing Documents

• osur-20241219.htm (8-K) — 33KB
• exhibit991_projwatsoninv.htm (EX-99.1) — 16KB
• exhibit992_projwatsonpress.htm (EX-99.2) — 18KB
• exhibit991_projwatsoninv001.jpg (GRAPHIC) — 81KB
• exhibit991_projwatsoninv002.jpg (GRAPHIC) — 290KB
• exhibit991_projwatsoninv003.jpg (GRAPHIC) — 152KB
• exhibit991_projwatsoninv004.jpg (GRAPHIC) — 107KB
• exhibit991_projwatsoninv005.jpg (GRAPHIC) — 123KB
• exhibit991_projwatsoninv006.jpg (GRAPHIC) — 78KB
• exhibit991_projwatsoninv007.jpg (GRAPHIC) — 102KB
• exhibit991_projwatsoninv008.jpg (GRAPHIC) — 93KB
• exhibit991_projwatsoninv009.jpg (GRAPHIC) — 114KB
• exhibit991_projwatsoninv010.jpg (GRAPHIC) — 94KB
• exhibit991_projwatsoninv011.jpg (GRAPHIC) — 157KB
• image_0a.jpg (GRAPHIC) — 20KB
• 0001116463-24-000051.txt ( ) — 2146KB
• osur-20241219.xsd (EX-101.SCH) — 2KB
• osur-20241219_lab.xml (EX-101.LAB) — 21KB
• osur-20241219_pre.xml (EX-101.PRE) — 12KB
• osur-20241219_htm.xml (XML) — 3KB

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. OraSure Technologies, Inc. (the "Company") hereby furnishes the Investor Presentation that the Company will present to analysts and investors on or after the date hereof, which is attached as Exhibit 99.1 to this Current Report on Form 8-K ("Current Report"), is incorporated herein by reference and will be available on the Company's website at www.orasure.com. The information in this Item and attached Exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report or attached Exhibit.

01 Other Events

Item 8.01 Other Events. On December 19, 2024, the Company issued a press release announcing the Company's acquisition of Sherlock Biosciences, Inc ("Sherlock"). A copy of the press release is attached as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

Forward Looking Statements

Forward Looking Statements This Current Report contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the Company's acquisition of Sherlock, revenue growth, cash flow, increasing margins and other matters. Words such as "expects," "estimates," "forecasts," "intends," "plans," "projects," "could," "may," "should," "will" or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: the Company's ability to integrate Sherlock's business and achieve the intended benefits of the acquisition on the timeline expected or at all; Sherlock's ability to seek and obtain regulatory approval for products in development; the Company's ability to satisfy customer demand; ability to reduce the Company's spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company's business restructuring, including from insourcing third party manufacturing and exiting microbiome services; ability to market and sell products, whether through the Company's internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indi

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation 99.2 Press Release, dated December 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORASURE TECHNOLOGIES, INC. Date: December 19, 2024 By: /s/ Carrie Eglinton Manner Carrie Eglinton Manner President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR